Here Are Big Pharma's Leading Blockbuster Makers
GSK's Marketing Authorization Application for Blenrep Combinations Accepted for Review in EU
GSK (GSK) said Friday that the European Medicines Agency has accepted for review the marketing authorization application for Blenrep, in combination with bortezomib plus dexamethasone or
Blenrep (Belantamab Mafodotin) Combinations in Multiple Myeloma Application Accepted for Review by the European Medicines Agency
Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trialsTrials showed significant progression-free survival benefit and positive overall survival trends for Blenrep
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading
European equities traded in the US as American depositary receipts were lower late Wednesday morning, falling 1.33% to 1,437.22 on the S&P Europe Select ADR Index.From continental Europe, the
Global Drug Discovery Technologies Market Insights, 2024-2033 - Top 10 Companies Account for 26.61% of the Total Market; AstraZeneca Leads With 5.73% Share, Followed by Merck and GlaxoSmithKline
Unusual Options Activity: GOOG, BKR and Others Attract Market Bets, GOOG V/OI Ratio Reaches 357.1
EST Jul 11th Afternoon Delivery - In the last two hours of trading, 8 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
GSK to Deliver Over 36M Flu Shots for Fall Immunization Drive
GSK Begins Shipping Influenza Vaccine Doses for 2024-25 Season
GSK supports annual flu immunization by getting FLULAVAL and FLUARIX to patients in advance of flu season GSK plc (NYSE:GSK) today announced it has started shipping doses of its trivalent influenza vaccines to US
Is GSK an Attractive Drug Stock to Add to Your Portfolio Now?
GlaxoSmithKline (GSK) Receives a Buy From Deutsche Numis
GSK Plc (GSK): Is It the Best FTSE Dividend Stock to Buy According to Hedge Funds?
GSK Cut to Neutral From Buy by UBS
GSK Cut to Neutral From Buy by UBS
Express News | UBS Downgrades GSK to Neutral
ITeos Therapeutics Has Dosed First Patient In GALAXIES Lung-301 Phase 3 Trial Of Belrestotug+Dostarlimab Vs. Placebo+Pembrolizumab For First-line Advanced, Unresectable, Or Metastatic PD-L1 High Non-Small Cell Lung Cancer
This event has triggered $35 million in development milestone payments from GSK, its partner for belrestotug.iTeos and GSK entered into an exclusive development and commercialization collaboration in
Express News | GSK Says First Single-Dose Medicine To Prevent Relapse Of P. Vivax Malaria Launched In Thailand And Brazil
Express News | UPDATE: Circulations Of Report Titled 'FDA To Evaluate Potential Risk Of Neural Tube Birth Defects With HIV Medicine Dolutegravir (Juluca, Tivicay, Triumeq)' Was Originally Issued On September 6, 2018.; Shares Of GSK See Rebound From Lows
What the U.K. Election Means for Oil Stocks and Other Sectors -- Barrons.com
By Brian Swint U.K. voters gave the biggest election victory to the Labour Party since former Prime Minister Tony Blair's landslide win in 1997. If history is anything to go by, that could be a boon
Express News | 'FDA to Evaluate Potential Risk of Neural Tube Birth Defects With HIV Medicine Dolutegravir (Juluca, Tivicay, Triumeq)' - FDA
Markets Like Certainty. How the Biden and Trump Show Is Affecting Stocks, Bonds.
GSK's RSV Vaccine Sales Outlook Dims After CDC's Narrowed Recommendation -- Market Talk
0619 GMT - GSK's sales outlook for its respiratory syncytial virus vaccine, Arexvy, could take a blow after U.S. health officials narrowed their age recommendation for RSV shots last week, Citi analys
No Data